IndustryCompany release

Attovia posts positive 12-week Phase 1b ATTO-1310 itch data, plans 2027 Phase 2 trials; IPO lifts cash to $395.9M

🇺🇸 Attovia Therapeutics, Inc. (ATTO) · Mon 09 Nov 2026

On November 9, 2026, Attovia Therapeutics reported Q3 results and a corporate update. It announced positive 12-week Phase 1b topline data for the IL-31 antibody ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. The ATTUNE-CPUO Phase 2 design has been aligned with the FDA, and Phase 2 trials are expected to start in 1H 2027. Cash of about $395.9 million, boosted by an August 2026 IPO, is expected to fund operations into 2030.

Company's press release (SEC filing): Attovia Therapeutics, Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →